Natural Shrimp, Inc. Completes Successful Trial in Japan

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Natural Shrimp, Inc. successfully completed a 6-month trial in Japan using its patented Electrocoagulation (EC) and Hydrogas™ technologies, showing improved shrimp growth rates and effective removal of ammonia from water. The company aims to explore joint ventures, licensing, or business combinations in Japan based on the trial results.

Patented Electrocoagulation (EC) and Hydrogas™ Technologies Results from Trial at Aquaculture Farm in Japan

DALLAS, April 18, 2024 /PRNewswire/ -- Natural Shrimp, Inc. (OTCQB: SHMP) (the "Company" or "NSI"), a Biotechnology Aquaculture Company that has developed and patented the first seafood-focused commercially operational RAS (Recirculating Aquaculture System), today announced it has completed at the end of February 2024 a successful 6-month trial in Japan with the Company's patented Electrocoagulation (EC) and Hydrogas™ technologies (the "Equipment").

One week after arriving in Japan, the Natural Shrimp and Hydrenesis' team, with the assistance of the Japanese team, installed and began operating the Equipment at the Japanese shrimp research facility. The trial compared a tank treated by the EC and Hydrogas™ with a tank treated by a traditional biofilter. Throughout the 6-month trial, the EC effectively removed the ammonia from the water. In addition, the shrimp growth rate increased during the presence of Hydrogas when compared to the shrimp growth rate in the tank treated only by the biofilter.

Natural Shrimp supported the trial by making three (3) trips to Japan during the Trial Period and continued to actively participate in the Trial by remote access to the Equipment between trips. However, after initial instruction by the NSI team, the Japanese team was able to independently operate the EC and Hydrogas equipment on their own. The Japanese team performed extensive testing of the Equipment that included, among other things, collecting data under varying conditions by testing different flow rates, ammonia levels, and amperage levels. Based on the empirical results demonstrated by the Equipment during the Trial, Natural Shrimp looks to either joint venture, License or form a business combination in Japan.

Tom Untermeyer, Natural Shrimp Chief Technology Officer said, "I very much enjoyed working with the team in Japan during the installation and operation of our Equipment in the Japanese shrimp research facility. The Japanese quickly learned how to operate the EC and Hydrogas equipment and shared with us the data that they collected during the trial. The Japanese market is uniquely set up for the NSI technology based on its current shrimp import conditions and a robust consumption of shrimp as a primary protein source. I am excited to see where this will lead us in the future with the hope of helping them and others develop successful shrimp production systems using our technologies."

About Natural Shrimp

Natural Shrimp, Incorporated is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas, and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed salt-water systems using patented technology to produce fresh, naturally grown shrimp, without the use of antibiotics or toxic chemicals. Natural Shrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit www.naturalshrimp.com.

Forward-Looking Statements

This press release contains a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2022, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/natural-shrimp-inc-completes-successful-trial-in-japan-302120351.html

SOURCE NaturalShrimp Inc

FAQ

What technologies did Natural Shrimp, Inc. use in the trial in Japan?

Natural Shrimp, Inc. used its patented Electrocoagulation (EC) and Hydrogas™ technologies in the trial in Japan.

What were the results of the trial in Japan?

The trial showed improved shrimp growth rates and effective removal of ammonia from water using the EC and Hydrogas™ technologies.

How long was the trial conducted in Japan?

The trial in Japan lasted for 6 months.

What is the ticker symbol for Natural Shrimp, Inc.?

The ticker symbol for Natural Shrimp, Inc. is SHMP.

What is the focus of Natural Shrimp, Inc. as a company?

Natural Shrimp, Inc. is a Biotechnology Aquaculture Company that has developed and patented the first seafood-focused commercially operational RAS (Recirculating Aquaculture System).